0553 : Assessment of myocardial deformation using multi-layer speckle tracking in patients undergoing chemotherapy: a comparison of two vendors

详细信息    查看全文

• 作者：Yann Ancedy¹ ; Stephane Ederhy¹ ; ^{stephane.ederhy@aphp.fr" class="auth_mail" title="E-mail the corresponding author} ; Sylvie Lang¹ ; Antoine Hollebecque² ; Laurie Soulat-Dufour¹ ; Saroumadi Adavane-Scheuble¹ ; Marion Chauvet¹ ; Arnaud Etienney¹ ; Franck Boccara¹ ; Jean-Charles Soria² ; Ariel Cohen¹
• 刊名：Archives of Cardiovascular Diseases Supplements
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：8
• 期：3
• 页码：253-254
• 全文大小：124 K

文摘

The purpose of this study was to investigate intervendor variability when measuring multilayer strain in cancer patients treated with oral chemotherapy.

Methods

Patients enrolled to receive oral chemotherapy were prospectively included. Firstly, a same operator performed a 2 dimensional echocardiography within a delay of 10 minutes using Vivid 9 (Vendor A) and SC 2000 Siemens (Vendor B) ultrasound systems for each patient. Thereafter, we assessed myocardial deformation by using their respective speckle tracking softwares for strain multilayer measurement. Thus, we compared GLS multilayer values for the 2 vendors in each apical view (4c, 3c and 2c) and for each layer (endocardial, mid and epicardial layer). Comparisons between the 2 vendors were evaluated using intra class correlation coefficient.

Results

Eighty patients planned to receive chemotherapy were prospectively included between February and June 2015. Mean age was 55.3±16.3 years and 61% were female. Median left ventricular ejection fraction was 62% (57-66). Results of GLS multilayer values according to vendor, incidence, layer and their comparison are summarized in Table 1 There was a poor agreement between GLS multilayer as measured with GE system and Siemens system, whatever the layers, the incidence and the vendor.

Conclusion

We found a poor agreement for layer specific strain evaluation between GE and Siemens system using their dedicated softwares for strain multilayer assessment. These results suggest that in patient receiving chemotherapy the same system and software from the same vendor should be used for a longitudinal follow-up.

The author hereby declares no conflict of interest